The obesity drug industry has experienced a surge in growth over the past four years, with GLP-1 agonists emerging as a dominant force. Now, researchers are turning their attention to understanding and applying these drugs’ heart health benefits.
In March 2024, the FDA approved Novo Nordisk’s Wegovy (semaglutide) for reducing cardiovascular death, heart attack, and stroke risk in adults with cardiovascular disease and obesity or overweight. The Phase IIIb trial STRIDE is underway to evaluate semaglutide’s effects in patients with symptomatic peripheral artery disease.
Lilly is also conducting head-to-head comparisons of Zepbound (tirzepatide) against its older GLP-1 Trulicity (dulaglutide), looking at major adverse cardiovascular events. Meanwhile, Amgen’s MariTide has shown promise in Phase II trials for reducing weight loss and cardiovascular event risk.
Structure is developing an oral GLP-1R selective small molecule with a focus on off-target safety and efficacy. The company plans to propose additional cardiovascular outcome trials based on the candidate’s performance.
Experts emphasize the broad value of GLP-1s, highlighting their potential benefits beyond just weight loss and side effects. While further research is needed, the NIH reports over 400 active clinical studies involving GLP-1 intervention.
With an estimated $200 billion obesity drug market by 2031, the field is expected to continue growing, with 2025 being a pivotal year for small molecules, particularly GLP-1s.
Source: https://www.biospace.com/drug-development/evidence-mounts-for-benefit-of-glp-1s-against-heart-disease